postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial . J Clin Oncol 2000 ; 18 : 1399 – 1411 . 6 Bonneterre J Buzdar A Nabholtz JMA . Anastrozole is superior to tamoxifen as first-line therapy in
Search Results
Alyssa G. Rieber and Richard L. Theriault
Therese B. Bevers
. Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action . Clin Ther 2004 ; 26 : 830 – 840 . 4. Ettinger B Black DM Mitlak BH . Reduction of vertebral fracture risk in
Robert W. Carlson, Clifford A. Hudis, and Kathy I. Pritchard
. 12. Baum M . The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal (PM) women [abstract] . Breast Cancer Res Treat 2001 ; 69 : 8 . Abstract . 13. Baum M Budzar AU Cuzick J
Mohamed Ali Maher, Abdelhamid Mohamed Fouad, and Mariam Maged Elhaddad
endocrine therapies is preferred to the use of cytotoxic therapy whenever reasonable. Objective: To evaluate the efficacy and safety of generic Anastrozole in newly diagnosed postmenopausal female Egyptian patients with low burden visceral MBC and to
Amelia B. Zelnak and Ruth M. O'Regan
SOFT). For patients with chemotherapy-induced menopause, it is unknown whether similar benefit would be observed by switching from tamoxifen to an AI after postmenopausal status is confirmed, thereby eliminating the need for 5 years of ovarian
Kathleen Harnden and Kimberly Blackwell
-free survival events in patients who were more than 5 years since menopause at the time of trial entry (HR, 0.77; 0.63–0.96) but not in other menopausal groups, as seen in Table 2 . A trend was seen toward improved overall survival in the postmenopausal group
Jennifer A. Ligibel and Eric P. Winer
–3, 2000 . J Natl Cancer Inst Monogr 2001 ; 30 : 5 – 15 . 5 Geisler J Haynes B Anker G . Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a
Rowan T. Chlebowski, Aaron K. Aragaki, and Garnet L. Anderson
postmenopausal women were using these therapies. However, neither estrogen plus progestin nor estrogen alone had been evaluated in randomized clinical trials of sufficient size and power to prospectively evaluate the overall risk and benefit of their use
Tiffany H. Svahn, Joyce C. Niland, Robert W. Carlson, Melissa E. Hughes, Rebecca A. Ottesen, Richard L. Theriault, Stephen B. Edge, Anne F. Schott, Michael A. Bookman, and Jane C. Weeks
overview of the randomised trials . Lancet 2005 ; 365 : 1687 – 1717 . 2 Baum M . The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal (PM) women [abstract] . Breast Cancer Res Treat 2001
Senthil Damodaran, Ewa Mrozek, David Liebner, and Kari Kendra
high-dose IL-2 therapy Discuss the characteristic clinical presentation of TC Evaluate TC as differential diagnosis for patients, particularly postmenopausal women, who present with features suggestive of ischemia while on high-dose IL-2
